Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Humira

- PMLiVE

Facing the new wave of biosimilars

Don’t drown out the patient voice, says advocacy group

- PMLiVE

Sandoz joins Europe’s MabThera biosimilar push

Novartis’ unit is second company to claim approval in Europe for biosimilar version

- PMLiVE

AbbVie appoints new GMs for France and the UK

Jérôme Bouyer and Pierre-Claude Fumoleau take up new roles at the pharma firm

- PMLiVE

Pfizer gets FDA panel recommendation for biosimilar EPO

Product could be the first direct competitor to Epogen and Procrit in the US

- PMLiVE

WHO pilots scheme to make biosimilars available to poorer countries

Plans to expand prequalification scheme to medicines such as Roche’s Rituxan and Herceptin

- PMLiVE

Sandoz UK promotes Tim de Gavre to country head

He succeeds Stephan Eder who becomes country head for Sandoz Germany

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

- PMLiVE

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

Seeks FDA approval to treat GVHD patients

- PMLiVE

Amgen wins European approval for Humira biosimilar Amgevita

European Commission approves the first version of AbbVie's blockbuster

- PMLiVE

A new decade of disruption: meeting the biosimilar challgenge

Ten years after biosimilars first rocked their boat, how will biologics stay competitive?

- PMLiVE

Merck confirms sale of biosimilar division

German pharma group is in 'advanced discussions' with potential buyers

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links